## Orestes Vicente Forlenza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11461539/publications.pdf

Version: 2024-02-01

98 papers

2,665 citations

172457 29 h-index 197818 49 g-index

101 all docs

101 docs citations

101 times ranked

4376 citing authors

#	Article	IF	Citations
1	Increased Serum IL-1β Level in Alzheimer's Disease and Mild Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2009, 28, 507-512.	1.5	177
2	Physical Exercise in MCI Elderly Promotes Reduction of Pro-Inflammatory Cytokines and Improvements on Cognition and BDNF Peripheral Levels. Current Alzheimer Research, 2014, 11, 799-805.	1.4	150
3	Do CSF total tau, phosphorylated tau, and $\hat{l}^2$ -amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer's disease? A systematic review and meta-analysis of the literature. World Journal of Biological Psychiatry, 2008, 9, 172-182.	2.6	142
4	Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World Journal of Biological Psychiatry, 2010, 11, 774-780.	2.6	116
5	Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatric Disease and Treatment, 2013, 9, 493.	2.2	105
6	Transcranial Magnetic Stimulation to Address Mild Cognitive Impairment in the Elderly: A Randomized Controlled Study. Behavioural Neurology, 2015, 2015, 1-13.	2.1	97
7	Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 16-22.	3.2	93
8	Diagnostic transitions in mild cognitive impairment subtypes. International Psychogeriatrics, 2009, 21, 1088-1095.	1.0	86
9	Higher Serum sTNFR1 Level Predicts Conversion from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 22, 1305-1311.	2.6	85
10	Mood disorders in the elderly: prevalence, functional impact, and management challenges. Neuropsychiatric Disease and Treatment, 2016, Volume 12, 2105-2114.	2.2	82
11	Neurobiological pathways to Alzheimer's disease: Amyloid-beta, TAU protein or both?. Dementia E Neuropsychologia, 2009, 3, 188-194.	0.8	72
12	Decreased Neurotrophic Support is Associated with Cognitive Decline in Non-Demented Subjects. Journal of Alzheimer's Disease, 2015, 46, 423-429.	2.6	71
13	Profiles of functional deficits in mild cognitive impairment and dementia: benefits from objective measurement. Journal of the International Neuropsychological Society, 2010, 16, 297-305.	1.8	67
14	Eye movement analysis and cognitive processing: detecting indicators of conversion to Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2014, 10, 1273.	2.2	64
15	Mild cognitive impairment: cognitive screening or neuropsychological assessment?. Revista Brasileira De Psiquiatria, 2008, 30, 316-321.	1.7	63
16	Fear of falling and falls in older adults with mild cognitive impairment and Alzheimer's disease. Aging, Neuropsychology, and Cognition, 2015, 22, 312-321.	1.3	63
17	Interleukin- $1\hat{l}^2$ Serum Levels is Increased in Antidepressant-Free Elderly Depressed Patients. American Journal of Geriatric Psychiatry, 2010, 18, 172-176.	1.2	62
18	Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World Journal of Biological Psychiatry, 2010, 11, 550-555.	2.6	56

#	Article	IF	Citations
19	Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease. NeuroMolecular Medicine, 2015, 17, 326-332.	3.4	50
20	To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 248-256.	3.2	49
21	Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. Journal of Psychiatric Research, 2010, 44, 917-920.	3.1	49
22	Neurobiological Correlates of Apathy in Alzheimer's Disease and Mild Cognitive Impairment: A Critical Review. Journal of Alzheimer's Disease, 2014, 39, 633-648.	2.6	47
23	An intervention to reduce neuropsychiatric symptoms and caregiver burden in dementia: <scp>P</scp> reliminary results from a randomized trial of the tailored activity program–outpatient version. International Journal of Geriatric Psychiatry, 2019, 34, 1301-1307.	2.7	45
24	Cognitive training in older adults with Mild Cognitive Impairment: Impact on cognitive and functional performance. Dementia E Neuropsychologia, 2009, 3, 124-131.	0.8	44
25	Verbal fluency in the detection of mild cognitive impairment and Alzheimer's disease among Brazilian Portuguese speakers: the influence of education. International Psychogeriatrics, 2009, 21, 1081-1087.	1.0	42
26	Platelet GSK3B activity in patients with late-life depression: Marker of depressive episode severity and cognitive impairment?. World Journal of Biological Psychiatry, 2011, 12, 216-222.	2.6	42
27	Psychometric characteristics of the Rivermead Behavioural Memory Test (RBMT) as an early detection instrument for dementia and mild cognitive impairment in Brazil. International Psychogeriatrics, 2010, 22, 1003-1011.	1.0	41
28	Functional Mobility in a Divided Attention Task in Older Adults With Cognitive Impairment. Journal of Motor Behavior, 2015, 47, 378-385.	0.9	37
29	Combining functional scales and cognitive tests in screening for mild cognitive impairment at a university-based memory clinic in Brazil. Revista Brasileira De Psiquiatria, 2008, 30, 346-349.	1.7	31
30	Diagnosis of Mild Cognitive Impairment Revisited after One Year. Dementia and Geriatric Cognitive Disorders, 2009, 27, 224-231.	1.5	30
31	Cross-cultural Adaptation, Reliability and Validity of the DAFS-R in a Sample of Brazilian Older Adults. Archives of Clinical Neuropsychology, 2010, 25, 335-343.	0.5	30
32	Cognitive Reserve Relates to Functional Network Efficiency in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 255.	3.4	30
33	Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer's disease patients. International Journal of Geriatric Psychiatry, 2015, 30, 1230-1237.	2.7	29
34	Association of neuropsychiatric syndromes with global clinical deterioration in Alzheimer's disease patients. International Psychogeriatrics, 2016, 28, 779-786.	1.0	27
35	Protein levels of ADAM10, BACE1, and PSEN1 in platelets and leukocytes of Alzheimer's disease patients. European Archives of Psychiatry and Clinical Neuroscience, 2019, 269, 963-972.	3.2	27
36	Cognitive and structural cerebral changes in amnestic mild cognitive impairment due to Alzheimer's disease after multicomponent training. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 473-480.	3.7	25

#	Article	IF	Citations
37	The Brazilian version of the Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity in dementia. International Psychogeriatrics, 2013, 25, 1503-1511.	1.0	24
38	Language impairment in euthymic, elderly patients with bipolar disorder but no dementia. International Psychogeriatrics, 2008, 20, 687-696.	1.0	23
39	Post-acute sequelae of SARS-CoV-2 infection (PASC): a protocol for a multidisciplinary prospective observational evaluation of a cohort of patients surviving hospitalisation in Sao Paulo, Brazil. BMJ Open, 2021, 11, e051706.	1.9	23
40	Brain PET amyloid and neurodegeneration biomarkers in the context of the 2018 NIA-AA research framework: an individual approach exploring clinical-biomarker mismatches and sociodemographic parameters. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2666-2680.	6.4	21
41	Chronic Lithium Treatment Increases Telomere Length in Parietal Cortex and Hippocampus of Triple-Transgenic Alzheimer's Disease Mice. Journal of Alzheimer's Disease, 2018, 63, 93-101.	2.6	20
42	Cognitive–linguistic deficits in euthymic elderly patients with bipolar disorder. Journal of Affective Disorders, 2013, 150, 691-694.	4.1	19
43	Correlation between functional mobility and cognitive performance in older adults with cognitive impairment. Aging, Neuropsychology, and Cognition, 2018, 25, 23-32.	1.3	18
44	Intranetwork and internetwork connectivity in patients with Alzheimer disease and the association with cerebrospinal fluid biomarker levels. Journal of Psychiatry and Neuroscience, 2017, 42, 366-377.	2.4	17
45	Optimizing the CAMCOG test in the screening for mild cognitive impairment and incipient dementia: saving time with relevant domains. International Journal of Geriatric Psychiatry, 2011, 26, 403-408.	2.7	16
46	Visual Search Efficiency in Mild Cognitive Impairment and Alzheimer's Disease: An Eye Movement Study. Journal of Alzheimer's Disease, 2020, 75, 261-275.	2.6	16
47	Effects of a psychoeducational intervention in family caregivers of people with Alzheimer's disease. Dementia E Neuropsychologia, 2011, 5, 226-237.	0.8	14
48	Long-Term Lithium Treatment Increases cPLA2 and iPLA2 Activity in Cultured Cortical and Hippocampal Neurons. Molecules, 2015, 20, 19878-19885.	3.8	14
49	Protein Expression of BACE1 is Downregulated by Donepezil in Alzheimer's Disease Platelets. Journal of Alzheimer's Disease, 2016, 55, 1445-1451.	2.6	14
50	The use of the Clock Drawing Test in bipolar disorder with or without dementia of Alzheimer's type. Arquivos De Neuro-Psiquiatria, 2014, 72, 913-918.	0.8	13
51	Apolipoprotein E genotype is not associated with cognitive impairment in older adults with bipolar disorder. Bipolar Disorders, 2016, 18, 71-77.	1.9	11
52	Cognitive impairment and dementia in bipolar disorder. Frontiers in Bioscience - Elite, 2013, E5, 258-265.	1.8	11
53	Higher proportion of inactive $Gsk3\hat{l}^2$ in platelets of elderly patients with bipolar disorder: an effect of treatment?. Revista Brasileira De Psiquiatria, 2013, 35, 274-278.	1.7	10
54	Deficits in short-term memory binding are detectable in individuals with brain amyloid deposition in the absence of overt neurodegeneration in the Alzheimer's disease continuum. Brain and Cognition, 2021, 152, 105749.	1.8	9

#	Article	IF	CITATIONS
55	Assessment of impairment in activities of daily living in mild cognitive impairment using an individualized scale. Arquivos De Neuro-Psiquiatria, 2016, 74, 549-554.	0.8	8
56	Hippocampal subregional volume changes in elders classified using positron emission tomographyâ€based Alzheimer's biomarkers of βâ€amyloid deposition and neurodegeneration. Journal of Neuroscience Research, 2021, 99, 481-501.	2.9	6
57	Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects. Journal of Alzheimer's Disease, 2020, 78, 229-244.	2.6	5
58	Saccadic eye movements associated with executive function decline in mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e040036.	0.8	5
59	Adjunctive Therapy to Manage Neuropsychiatric Symptoms in Moderate and Severe Dementia: Randomized Clinical Trial Using an Outpatient Version of Tailored Activity Program. Journal of Alzheimer's Disease, 2021, 83, 475-486.	2.6	5
60	O5-04-03: Regular multimodal aerobic exercise reduces pro-inflammatory cytokines and improves BDNF peripheral levels and executive functions in elderly MCI individuals with different BDNF Val66Met genotypes., 2015, 11, P323-P323.		3
61	P1â€404: APOE Genotype Modifies The Effects of Aerobic Training on Brain Glucose Metabolism in Subjects with Mild Cognitive Impairment. Alzheimer's and Dementia, 2016, 12, P588.	0.8	2
62	[P1 $\hat{a}$ €"346]: EFFECTS OF AEROBIC EXERCISE ON PROGRESSION OF HIPPOCAMPAL VOLUME AND COGNITION IN AMNESTIC MILD COGNITIVE IMPAIRMENT DUE TO AD. Alzheimer's and Dementia, 2017, 13, P389.	0.8	2
63	Differences in structural and functional default mode network connectivity in amyloid positive mild cognitive impairment: a longitudinal study. Neuroradiology, 2022, 64, 141-150.	2.2	2
64	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study., 2015, 11, P297-P297.		1
65	[P3–133]: SYSTEMIC INFLAMMATION AND ALZHEIMER's DISEASE BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P985.	0.8	1
66	[P2â€"012]: THE TAILORED ACTIVITY PROGRAM FOR OUTPATIENTS (TAPâ€O) TO REDUCE NEUROPSYCHIATRIC SYMPTOMS AND CAREGIVER BURDEN IN A BRAZILIAN SAMPLE OF INDIVIDUALS WITH DEMENTIA: PRELIMINARY RESULTS OF A RANDOMIZED TRIAL. Alzheimer's and Dementia, 2017, 13, P608.	0.8	1
67	Role of gait and speed performance in predicting cognitive decline and dementia in people with Down syndrome: Preliminary findings. Alzheimer's and Dementia, 2020, 16, e047466.	0.8	1
68	P4-031: PLATELET APP RATIO IN AD PATIENTS TREATED WITH DONEPEZIL. , 2014, 10, P794-P794.		0
69	P3-126: Neuropsychiatric syndromes and global deterioration in Alzheimer's disease. , 2015, 11, P670-P670.		0
70	P2-218: Financial capacity in normal controls, mild cognitive impairment, and dementia: Assessing for clinical practice., 2015, 11, P577-P577.		0
71	P2â€133: Eye Movement Analysis in Preclinical Alzheimer's Disease: Oculomotor Parameters and their Relation to Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P662.	0.8	0
72	P1â€147: Donepezil Modulates Adam10 and Bace1 Expression in Platelets of Alzheimer's Disease Patients. Alzheimer's and Dementia, 2016, 12, P459.	0.8	0

#	Article	IF	CITATIONS
73	P2â€084: Effect of Chronic Lithium Treatment on Telomeric Length in Tripleâ€Transgenic Alzheimer's Disease MICE. Alzheimer's and Dementia, 2016, 12, P641.	0.8	0
74	P1â€038: Proteomic Analysis of Hippocampal Cell Culture With Low Doses of Lithium Treatment. Alzheimer's and Dementia, 2016, 12, P415.	0.8	0
75	P1â€124: Lithium Treatment Prevents Amyloid Toxicity and MIRâ€489 Downâ€Regulation in an Alzheimer's Disease <i>in Vitro</i> MODEL. Alzheimer's and Dementia, 2016, 12, P451.	0.8	0
76	[P2–427]: DEPRESSION AND CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER's PATHOLOGY IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P799.	0.8	0
77	[P2–460]: IS THE CAMBRIDGE COGNITIVE TEST (CAMCOG) A USEFUL TOOL TO PREDICT THE PATHOLOGICAL STATUS OF CEREBROSPINAL FLUID IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT (MCI)?. Alzheimer's and Dementia, 2017, 13, P816.	0.8	O
78	[P3â€"296]: ARE CEREBROSPINAL FLUID BIOMARKERS A USEFUL TOOL TO DISCRIMINATE PATIENTS WITH MILD COGNITIVE IMPAIRMENT FROM HEALTHY INDIVIDUALS WITH NO COGNITIVE DETERIORATION?. Alzheimer's and Dementia, 2017, 13, P1056.	0.8	0
79	[P3–486]: ALZHEIMER's DISEASE: THE SENSE OF CARE AND DIFFICULTIES EXPERIENCED BY CAREGIVERS. Alzheimer's and Dementia, 2017, 13, P1161.	0.8	O
80	[P4–150]: COMORBIDITIES IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT WERE NOT RELATED TO AD PATHOLOGY ACCORDING TO CEREBROSPINAL FLUID BIOMARKERS. Alzheimer's and Dementia, 2017, 13, P1315.	0.8	0
81	[P4–156]: EYE MOVEMENT BEHAVIOR IN EARLY ALZHEIMER'S DISEASE: THE IMPACT OF TIME AND STIMULI SIMILARITY AS A MEASURE OF COGNITIVE EFFORT. Alzheimer's and Dementia, 2017, 13, P1318.	0.8	O
82	[P2–253]: EYE MOVEMENT BEHAVIOR IN MCI AND AD: USING AUTOMATIC CLASSIFICATION ALGORITHMS TO IDENTIFY COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P709.	0.8	0
83	P2â€575: FRAILTY SYNDROME IN ALZHEIMER'S DISEASE, MILD COGNITIVE IMPAIRMENT AND NORMAL AGING: CORRELATION WITH EXECUTIVE FUNCTION. Alzheimer's and Dementia, 2018, 14, P956.	0.8	O
84	P1â€629: CORRELATION BETWEEN FALLS AND GAIT SPEED DURING A DIVIDED ATTENTION TASK IN OLDER ADULTS WITH COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2018, 14, P582.	0.8	0
85	Screening for dementia in Down syndrome using the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Alzheimer's and Dementia, 2020, 16, e037381.	0.8	0
86	Differences in structural and functional DMN connectivity in amyloidâ€positive AMCI who converted to AD dementia. Alzheimer's and Dementia, 2020, 16, e041219.	0.8	0
87	Differences in functional connectivity in mild cognitive impairment for amyloidâ€positive versus SNAP. Alzheimer's and Dementia, 2020, 16, e042600.	0.8	O
88	Hippocampal connectivity may predict cholinesterase inhibitors response in mild Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042675.	0.8	0
89	Low doses of lithium and gene ontology analysis: Different action of dose response in neurons. Alzheimer's and Dementia, 2020, 16, e042941.	0.8	0
90	Protein levels of APP, ADAM10 and BACE1 in aging adults with Down syndrome: Preliminary findings. Alzheimer's and Dementia, 2020, 16, e043190.	0.8	0

#	Article	IF	CITATIONS
91	Platelet APPâ€ratio correlates with CSF levels of Aβ1â€42 in Alzheimer's disease patients. Alzheimer's and Dementia, 2020, 16, e043212.	0.8	0
92	Platelet APP levels from subjects with Alzheimer's disease and mild cognitive impairment. Alzheimer's and Dementia, 2020, 16, e043436.	0.8	0
93	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: A mass spectrometry study. Alzheimer's and Dementia, 2020, 16, e043519.	0.8	O
94	Alzheimer's disease: Donepezil effects on cholesterol and oxysterol plasma levels. Alzheimer's and Dementia, 2020, 16, e044144.	0.8	0
95	Depressão e ansiedade em adultos e idosos com sÃndrome de Down: Resultados preliminares de um estudo prospectivo no Brasil. Alzheimer's and Dementia, 2020, 16, e047615.	0.8	O
96	Textual Inference Comprehension in Mild Cognitive Impairment: The Influence of Semantic Processing and Verbal Episodic Memory. Frontiers in Aging Neuroscience, 2021, 13, 735633.	3.4	0
97	Pattern of proteolytic processing of Amyloid Precursor Protein in Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.8	0
98	Oxidative stress biomarkers in individuals with Down syndrome: Implications to the pathogeny of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0